Why One Value Fund Just Bought $30 Million of a Diagnostics Stock Down 90% From Pandemic-Era Highs

Newtyn Management disclosed a purchase of 994,332 QuidelOrtho (QDEL) shares in Q3, increasing its position to 2.7 million shares valued at $79.5 million as of Sept. 30 — representing 9.7% of the fund’s $816.9 million 13F-reportable assets. QuidelOrtho shares trade at $27.76 (down 26% Y/Y) after a $701 million goodwill impairment, though underlying metrics showed some stabilization: non-respiratory revenue +5%, lab revenue +5%, adjusted EBITDA margin expanded to 25%, and adjusted EPS of $0.80. The filing signals a high‑conviction, value‑oriented bet on operational recovery but carries execution risk as COVID-related revenues decline and the company resets guidance and balance-sheet writedowns.

Analysis

Market structure: Newtyn’s 2.7M-share stake (worth $79.5M at 9.7% of its 13F assets) signals high-conviction value buying in a deeply discounted diagnostics name. Winners include Newtyn if QDEL sustains non-respiratory lab and consumables growth (TTM revenue $2.7B, adj. EBITDA margin 25%), suppliers of recurring consumables that preserve pricing power, and potential acquirers hunting cheap strategic assets; losers are short-term momentum funds and holders of QDEL equity if goodwill impairments and sentiment keep multiple depressed.

Risk assessment: Tail risks include an FDA adverse action, meaningful reimbursement cuts, additional goodwill or asset writedowns (> $700M precedent), or a cash-flow shock that forces asset sales. Immediate (days) risk is headline-driven volatility; short-term (weeks–months) hinges on upcoming guidance and analyst revisions; long-term (quarters–years) depends on stabilization of non-respiratory revenue and repeatable consumables margins. Hidden dependencies: donor-screening wind-down and legacy COVID revenue tails that mask true consumables churn.

Trade implications: Tactical, size-constrained exposure is preferable to full conviction long — equity with options hedges or LEAPs for asymmetric upside. Pair trades versus large diversified diagnostics (e.g., DHR) can isolate idiosyncratic recovery; credit spreads likely widen if equity falls, creating separate opportunities in bonds/CDS. Watch implied vol and liquidity: options become expensive on 20–40% swings, so prefer calendar spreads or buy-writes funded by selling short-dated premium.

Contrarian angles: Consensus prices in secular decline and ignores 5% lab revenue growth and 25% adjusted EBITDA margin — a classic “operational recovery + valuation reset” setup if the firm repeats margin gains. Reaction may be overdone if next two quarters show sequential margin expansion; downside is underappreciated too (further impairments). Historical parallel: post-COVID diagnostics names (e.g., Hologic, Bio-Rad) saw multi-quarter troughs followed by selective recoveries driven by consumables, suggesting a 6–18 month horizon for re-rating if KPIs hold.

Key Decisions for Investors

• Establish a tactical long in QDEL equal to 1–2% of portfolio at market up to $28; add up to 3% total if the next two quarters show sequential non-respiratory revenue growth (>3% q/q annualized) and adj. EBITDA margin >=26%. Set a hard sell if price trades below $20 for 10 consecutive sessions or if cash burn forces liquidity raise.
• Buy Jan 17, 2026 $25 LEAP calls (size ~0.5% of portfolio) for asymmetric upside, funded by selling Jan 17, 2025 $40 calls to offset premium (~30% financing). Close or roll if implied vol >50% or if company misses guidance by >5% on revenue or EBITDA in the next quarterly report.
• Implement a relative-value pair: long QDEL / short Danaher (DHR) equal-dollar notional for 6–12 months to isolate idiosyncratic recovery; trim if QDEL outperforms DHR by +50% or if the EV/EBITDA gap compresses by 50% versus current gap.
• Avoid/short QDEL credit if corporate bond spreads widen >600bp over Treasuries or if a formal downgrade to junk occurs; consider buying CDS protection as a hedge rather than financing equity exposure if downside risk materializes.